keyword
MENU ▼
Read by QxMD icon Read
search

certolizumab

keyword
https://www.readbyqxmd.com/read/29343510/limited-radiographic-progression-and-sustained-reductions-in-mri-inflammation-in-patients-with-axial-spondyloarthritis-4-year-imaging-outcomes-from-the-rapid-axspa-phase-iii-randomised-trial
#1
Désirée van der Heijde, Xenofon Baraliakos, Kay-Geert A Hermann, Robert B M Landewé, Pedro M Machado, Walter P Maksymowych, Owen R Davies, Natasha de Peyrecave, Bengt Hoepken, Lars Bauer, Tommi Nurminen, Juergen Braun
OBJECTIVES: To report 4-year imaging outcomes in the RAPID-axSpA (NCT01087762) study of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), treated with certolizumab pegol (CZP). METHODS: This phase III, randomised trial was placebo-controlled and double-blind to week 24, dose-blind to week 48 and open-label to week 204. Patients fulfilling the Assessment of Spondyloarthritis International Society (ASAS) axSpA criteria with active disease were stratified (AS/nr-axSpA) according to the modified New York (mNY) criteria at randomisation...
January 17, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29335342/comparative-efficacy-of-tumor-necrosis-factor-%C3%AE-inhibitors-in-ankylosing-spondylitis-a-systematic-review-and-bayesian-network-metaanalysis
#2
Runsheng Wang, Abhijit Dasgupta, Michael M Ward
OBJECTIVE: To compare the efficacy of 6 tumor necrosis factor-α inhibitors (TNFi) in treatment of ankylosing spondylitis (AS) at 12 weeks and 24 weeks. METHODS: We performed a systematic literature review of randomized controlled trials of TNFi in patients with active AS. We included trials that reported efficacy at 10 to 14 weeks (12-week analysis) and at 24 to 30 weeks (24-week analysis). We used Bayesian network metaanalysis (NMA) to compare their relative efficacy to improve the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and C-reactive protein (CRP) level...
January 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29332708/management-of-psoriasis-in-patients-with-inflammatory-bowel-disease-from-the-medical-board-of-the-national-psoriasis-foundation
#3
REVIEW
Scott M Whitlock, Clinton W Enos, April W Armstrong, Alice Gottlieb, Richard G Langley, Mark Lebwohl, Joseph F Merola, Caitriona Ryan, Michael P Siegel, Jeffrey M Weinberg, Jashin J Wu, Abby S Van Voorhees
BACKGROUND: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. OBJECTIVE: To assess therapeutic options for patients with psoriasis and concurrent IBD. METHODS: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017...
February 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29329557/one-year-risk-of-serious-infection-in-patients-treated-with-certolizumab-pegol-as-compared-with-other-tnf-inhibitors-in-a-real-world-setting-data-from-a-national-u-s-rheumatoid-arthritis-registry
#4
Leslie R Harrold, Heather J Litman, Katherine C Saunders, Kimberly J Dandreo, Bernice Gershenson, Jeffrey D Greenberg, Robert Low, Jeffrey Stark, Robert Suruki, Srihari Jaganathan, Joel M Kremer, Mohamed Yassine
BACKGROUND: Registry studies provide a valuable source of comparative safety data for tumor necrosis factor inhibitors (TNFi) used in rheumatoid arthritis (RA), but they are subject to channeling bias. Comparing safety outcomes without accounting for channeling bias can lead to inaccurate comparisons between TNFi prescribed at different stages of the disease. In the present study, we examined the incidence of serious infection and other adverse events during certolizumab pegol (CZP) use vs other TNFi in a U...
January 2, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29321825/umbilical-cord-blood-stem-cell-treatment-for-a-patient-with-psoriatic-arthritis
#5
Margaret Coutts, Rowena Soriano, Rajendran Naidoo, Habib Torfi
Clinical and laboratory results document psoriatic arthritis in a 56-year old patient. The symptoms did not resolve with standard treatments (nonsteroidal anti-inflammatory drugs, steroids and methotrexate). TNF-alpha inhibitors (certolizumab pegol and adalimumab) were added to the treatment regime, with some adverse effects. A trial of human umbilical cord stem cell therapy was then initiated. The stem cells were enriched and concentrated from whole cord blood, by removal of erythrocytes and centrifugation...
December 26, 2017: World Journal of Stem Cells
https://www.readbyqxmd.com/read/29308279/the-real-world-use-of-different-anti-tumor-necrosis-factor-agents-in-a-northern-european-population-of-patients-with-beh%C3%A3-et-s-disease
#6
Fahd Adeeb, Wan Lin Ng, Maria Usman Khan, Joseph Devlin, Austin G Stack, Alexander Duncan Fraser
Objective: The aim of this study was to evaluate prescription practices, treatment responses, and serious adverse events of anti-tumor necrosis factor (anti-TNF) therapies in Behçet's disease (BD). Material and Methods: Patients with BD satisfying the International Study Group for Behçet's Disease or the International Criteria for Behçet's Disease criteria were recruited from a regional rheumatology program. The choice of anti-TNF, treatment response, and adverse events were specified...
December 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/29294598/rapid-onset-of-efficacy-predicts-response-to-therapy-with-certolizumab-plus-methotrexate-in-patients-with-active-rheumatoid-arthritis
#7
Young Mo Kang, Young-Eun Park, Won Park, Jung-Yoon Choe, Chul-Soo Cho, Seung-Cheol Shim, Sang Cheol Bae, Chang-Hee Suh, Hoon-Suk Cha, Eun Mi Koh, Yeong-Wook Song, Bin Yoo, Shin-Seok Lee, Min-Chan Park, Sang-Heon Lee, Catherine Arendt, Willem Koetse, Soo-Kon Lee
Background/Aims: The objective of this study was to determine the efficacy and safety of add-on therapy with certolizumab pegol (CZP) in active rheumatoid arthritis (RA) patients of a single ethnicity. Methods: In this 24-week, phase 3, randomized, double-blind, placebo-controlled trial, eligible patients (n = 127) were randomized 2:1 to subcutaneous CZP + methotrexate (MTX; 400 mg at week 0, 2, and 4 followed by 200 mg every 2 weeks) or placebo + MTX. Results: At week 24, the American College of Rheumatology criteria for 20% (ACR20) response rate was significantly greater with CZP + MTX than with placebo (66...
January 5, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29290076/risk-of-serious-infections-in-biological-treatment-of-patients-with-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-a-meta-analysis
#8
Sen Wang, Qian He, Zongwen Shuai
The objective of the study is to quantitatively assess the risk of serious infections in patients with axial spondyloarthritis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) treated by biologics enrolled in randomized controlled trials (RCTs). A systematic literature searches of MEDLINE (via PubMed), EMBASE, the Cochrane Library and abstracts archives of the annual scientific meetings of both the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) was conducted through October 2015...
December 30, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29278210/biologics-in-inflammatory-and-immunomediated-arthritis
#9
Michele Maria Luchetti, Devis Benfaremo, Armando Gabrielli
BACKGROUND: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis. METHODS: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases...
December 26, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29247389/degree-of-prescriber-s-knowledge-about-variability-in-biological-drugs-innovators-in-manufacturing-process
#10
Lucía Jiménez-Pichardo, Rocío Gázquez-Pérez, Jesús Francisco Sierra-Sánchez
PURPOSE: The purpose of the study is to analyse the degree of prescribers' knowledge about the regulation and variability in manufacturing processes (MP) in bio-drugs "innovators" (BI). METHODS: For each selected drugs, the date of authorization by the European Medicines Agency, time elapsed until the first change, total number of changes and annual rate of change (ARC) were recorded. A survey was designed with 4 parts: (a) identifying the BI prescribed; (b) knowledge of the number and ARC of each BI during its MP; (c) knowledge of comparability requirement of BI before or after the MP; (d) evaluating the utility of the information in the survey...
December 15, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29246162/use-of-a-baseline-risk-score-to-identify-the-risk-of-serious-infectious-events-in-patients-with-rheumatoid-arthritis-during-certolizumab-pegol-treatment
#11
Jeffrey R Curtis, Kevin Winthrop, Cathy O'Brien, Matladi N Ndlovu, Marc de Longueville, Boulos Haraoui
BACKGROUND: The risk of serious infectious events (SIEs) is increased in patients with rheumatoid arthritis (RA). The aim of this study was to develop an age-adjusted comorbidity index (AACI) to predict, using baseline characteristics, the SIE risk in patients with RA treated with certolizumab pegol (CZP). METHODS: Data of CZP-treated patients with RA were pooled from the RAPID1/RAPID2 randomized controlled trials (RCT CZP) and their open-label extensions (All CZP)...
December 15, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29232326/certolizumab-pegol-induced-heart-failure
#12
Karina Lazarewicz, Steven Shaw, Sahena Haque
No abstract text is available yet for this article.
December 12, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29231192/defining-an-optimal-adherence-threshold-for-patients-taking-subcutaneous-anti-tnfs-for-inflammatory-bowel-diseases
#13
Shail M Govani, Mohamed Noureldin, Peter D R Higgins, Michele Heisler, Sameer D Saini, Ryan W Stidham, Jennifer F Waljee, Akbar K Waljee
OBJECTIVES: In patients with inflammatory bowel disease (IBD) using biological therapy, non-adherence leads to anti-drug antibody formation and reduced effectiveness. Little is known about the optimal level of adherence in IBD patients on biologic therapy. We aimed to identify the association between adherence and disease flare and determine an optimal level of adherence. METHODS: We analyzed claims data for IBD patients prescribed adalimumab (ADA) and certolizumab (CZP) from the Truven Health MarketScan Commercial Claims and Encounters database from 2009 to 2013...
December 12, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29222625/using-patient-feedback-to-optimize-the-design-of-a-certolizumab-pegol-electromechanical-self-injection-device-insights-from-human-factors-studies
#14
Barbara Domańska, Oliver Stumpp, Steven Poon, Serkan Oray, Irina Mountian, Clovis Pichon
INTRODUCTION: We incorporated patient feedback from human factors studies (HFS) in the patient-centric design and validation of ava®, an electromechanical device (e-Device) for self-injecting the anti-tumor necrosis factor certolizumab pegol (CZP). METHODS: Healthcare professionals, caregivers, healthy volunteers, and patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or Crohn's disease participated in 11 formative HFS to optimize the e-Device design through intended user feedback; nine studies involved simulated injections...
December 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29218754/cutaneous-leishmaniasis-mimicking-dactylitis-in-a-patient-with-rheumatoid-arthritis-treated-with-certolizumab
#15
J Herrerias-Moreno, V Expósito-Serrano, E Agut-Busquet, M Corbacho, E Sáez, J Luelmo
No abstract text is available yet for this article.
December 8, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29205904/dosing-down-and-then-discontinuing-biologic-therapy-in-rheumatoid-arthritis-a-review-of-the-literature
#16
REVIEW
Der-Yuan Chen, Chak Sing Lau, Bassel Elzorkany, Ping-Ning Hsu, Sonja Praprotnik, Radu Vasilescu, Lisa Marshall, Lyndon Llamado
AIM: To review the published studies that dose down and then discontinue biologic therapy in patients with rheumatoid arthritis (RA), particularly concerning the criteria for such dosing and the impact on clinical outcomes. METHODS: Published studies conducted in patients with RA that sequentially decreased the dose and then discontinued therapy were included if one or more of the following biologic disease modifying antirheumatic drugs (bDMARDs) was evaluated: abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab or tocilizumab...
December 4, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29177802/correction-to-certolizumab-pegol-in-the-treatment-of-psoriasis-and-psoriatic-arthritis-preliminary-real-life-data
#17
Annunziata Dattola, Maria Vittoria Cannizzaro, Mauro Mazzeo, Luca Bianchi
In the original publication, part Fig. 3b and c were interchanged. The correct versions are given below.
November 25, 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/29159893/exposure-response-relationship-of-certolizumab-pegol-induction-and-maintenance-therapy-in-patients-with-crohn-s-disease
#18
N Vande Casteele, B G Feagan, S Vermeire, M Yassine, J Coarse, G Kosutic, W J Sandborn
BACKGROUND: Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM: To use a population pharmacokinetic model that accounts for the time-varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure-response relationship for CZP in Crohn's disease. METHODS: Adults (N = 2157) with Crohn's disease were treated with CZP in nine clinical trials. Simulated CZP concentrations were compared to outcomes at weeks 6 and 26, including Crohn's disease activity index (CDAI) response (decrease from baseline ≥ 100 points), remission (CDAI ≤ 150), C-reactive protein (CRP) ≤ 5 mg/L, faecal calprotectin (FC) ≤ 250 μg/g, and a composite endpoint of CDAI ≤ 150 and FC ≤ 250 μg/g...
November 21, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29141665/matrix-metalloproteinase-3-and-the-7-joint-ultrasound-score-in-the-assessment-of-disease-activity-and-therapeutic-efficacy-in-patients-with-moderate-to-severe-rheumatoid-arthritis
#19
Ling Zhou, Geng Wang, Xin Liu, Jing Song, Ling Chen, Huji Xu
BACKGROUND: This study aimed to investigate the reliability and validity of serum matrix metalloproteinase-3 (MMP-3) levels and articular ultrasound (US) scores in assessing disease activity and therapeutic response in rheumatoid arthritis (RA) patients. METHODS: A total of 151 RA patients were enrolled, of whom 22 were treated with certolizumab pegol (Cimzia, CZP). The RA patients were divided into the following four subgroups according to their disease activity score in 28 joints (DAS28): stable, mild activity, moderate activity, and high activity...
November 15, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29139035/certolizumab-pegol-in-the-treatment-of-psoriasis-and-psoriatic-arthritis-preliminary-real-life-data
#20
Annunziata Dattola, Maria Vittoria Cannizzaro, Mauro Mazzeo, Luca Bianchi
INTRODUCTION: We present the results of real-life tests conducted in adults affected by psoriatic arthritis (PsA) with mild cutaneous involvement to evaluate the efficacy of certolizumab pegol (CZP), an anti-tumor necrosis factor-alpha agent approved in Europe for the treatment of rheumatoid arthritis and PsA. METHODS: Assessments included an evaluation of the Psoriasis Area and Severity Index (PASI) and the Disease Activity Score computed on 44 joints (DAS-44) correlated to the erythrocyte sedimentation rate (ESR) (DAS44-ESR)...
December 2017: Dermatology and Therapy
keyword
keyword
7417
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"